Notable Labs Acquires VBL Therapeutics
Notable Labs, Inc. announced its acquisition of VBL Therapeutics on February 23. Notable’s stockholders will receive newly issued ordinary shares and investors have committed an additional $10.3 million in a private placement to Notable, led by Builders VC, B Capital Group, Y Combinator, First Round Capital & Founders Fund. Chardan Capital Markets LLC is serving as the exclusive financial advisor to VBL Therapeutics, and Goodwin Procter LLP and Horn & Co. are serving as legal counsel to VBL Therapeutics. JMP Securities LLC is serving as exclusive financial advisor for Notable and Wiggin and Dana LLP and Meitar are serving as legal counsel to Notable. The combined company is... Read More »
Donaldson Company Purchases Isolere Bio
Donaldson Company, Inc. announced on February 21 that it acquired Durham, North Carolina-based Isolere Bio, Inc. With the addition of Isolere to Donaldson’s portfolio, Donaldson is positioned to create premier separation and filtration solutions for emerging genetic-based drugs. The financial terms of the acquisition were not disclosed. Isolere Bio is an early-stage biotechnology company that develops novel and proprietary IsoTag reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals. It was founded in 2017 by Kelli Luginbuhl, Ph.D, Professor Ashutosh Chilkoti and Joe McMahon. Founded in 1915, Donaldson Company is a... Read More »
Bavarian Nordic Acquires Emergent BioSolutions’ Travel Health Business for up to $380 Million
Bavarian Nordic has acquired Emergent BioSolutions’ travel health business for up to $380 million. Upon closing of the transaction, Bavarian Nordic will pay Emergent $270 million in upfront cash consideration. Bavarian Nordic will also pay Emergent up to $30 million in sales-based milestones associated with commercial products and up to $80 million in development-based milestones associated with the CHIKV VLP program. Bavarian Nordic will acquire Emergent’s manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 Emergent employees are expected to join Bavarian Nordic as part of the transaction that is expected to close in... Read More »
ReLive Biotechnologies Acquires Co.Don AG
China-based ReLive Biotechnologies, Ltd. has acquired Germany-based Co.Don AG. Terms of the deal were not disclosed. ReLive Biotechnologies is taking over the global patent rights of Spherox and Chondrosphere. Spherox is one of two authorized cell therapies for the regenerative treatment of articular cartilage defects globally. Co.Don AG is a biopharmaceutical company that develops, produces and markets cell-based pharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. According to data captured in the LevinPro HC database, this acquisition represents the 16th Biotechnology deal of 2023. There were 141 Biotechnology... Read More »
Sun Pharmaceutical Industries Acquires Concert Pharmaceuticals in $576 Million Deal
Sun Pharmaceutical Industries Limited has acquired Concert Pharmaceuticals, Inc. for $576 million. Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8 per share of common stock in cash. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share of common stock in cash, payable upon Concert’s candidate deuruxolitinib achieving certain net sales milestones within specified periods, subject to the terms and conditions contained in a contingent value rights agreement detailing the terms of the CVRs. Concert is a late-stage clinical... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
